1. Scrip
  2. >>Leadership

Interview: Almirall CEO Guenter Plots 'Play To Win' Future

 
• By Eleanor Malone

Peter Guenter has steadied the ship at Almirall, and after seven months in the role he outlines his vision for the company in his first exclusive interview as CEO of Spain's largest pharma company.

Almirall headquarters
Guenter has high hopes for Almirall • Source: Almirall

Peter Guenter has just finalized his five-year plan for Almirall SA after taking time to understand the company in his first seven months as CEO. In his first exclusive interview since joining the company, he tells Scrip about his vision for the dermatology-focused, family-controlled Spanish company.

When Guenter's appointment was announced, Almirall was reeling from damaging developments in its US business which had dragged down its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

In partnership with

Podcast Series: Navigating Regulatory & Market Shifts — CRO Perspectives on Clinical Trials

Insights from Novotech on Evolving Trends Impacting Global Clinical Development

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

 
• By Kevin Grogan

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

 
• By Anju Ghangurde

Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.